Skip to main
HCAT

HCAT Stock Forecast & Price Target

HCAT Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 0%
Buy 11%
Hold 89%
Sell 0%
Strong Sell 0%

Bulls say

Health Catalyst is facing temporary headwinds due to its transition and restructuring within its professional services segment, leading to a decrease in revenue in the short term. However, its strong customer retention and potential for divestitures in its application assets position the company for long-term growth and profitability. Despite some challenges in the end market and negative mix shift, Health Catalyst's flagship offering and recurring revenue from its applications provide stability and potential for shareholder value.

Bears say

Health Catalyst is currently facing several challenges, including a decrease in FY27 revenue and adj. EBITDA estimates, as well as a step down in revenue from 2Q26 guidance due to DOS-to-Ignite migration/down-sell risk and broader ARR retention pressure. Additionally, the health system end-market is facing financial pressure which could reduce the budget availability for technology investments, potentially leading to decreased demand for Health Catalyst's offerings. In terms of competition, the company faces both home-grown solutions from health systems and competition from larger technology and EHR companies in the data platform and warehouse space, as well as from consultancies in the services segment.

HCAT has been analyzed by 9 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 11% recommend Buy, 89% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Health Catalyst Inc (HCAT) Forecast

Analysts have given HCAT a Hold based on their latest research and market trends.

According to 9 analysts, HCAT has a Hold consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Health Catalyst Inc (HCAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.